APA (7th ed.) Citation

Grünwald, V., Ivanyi, P., Zschäbitz, S., Wirth, M., Staib, P., Schostak, M., . . . Grüllich, C. (2023). Nivolumab switch maintenance therapy after tyrosine kinase inhibitor induction in metastatic renal cell carcinoma: A randomized clinical trial by the interdisciplinary working group on renal tumors of the German cancer society (NIVOSWITCH; AIO-NZK-0116ass). European urology, 84(6), . https://doi.org/10.1016/j.eururo.2023.09.004

Chicago Style (17th ed.) Citation

Grünwald, Viktor, et al. "Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass)." European Urology 84, no. 6 (2023). https://doi.org/10.1016/j.eururo.2023.09.004.

MLA (9th ed.) Citation

Grünwald, Viktor, et al. "Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass)." European Urology, vol. 84, no. 6, 2023, https://doi.org/10.1016/j.eururo.2023.09.004.